| Year |
Kyowa Hakko |
| 2008 |
- Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.
- Capital alliance with Kirin Pharma.
|
| 2007 |
- Announced a strategic alliance between Kyowa Hakko Group and Kirin Group.
- Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.
- Release of the anti-epileptic drug Topina.
|
| 2006 |
- Release of Patanol, an anti-allergic eye drops.
- Release of Bothdel, an MRI contrast medium for the gastrointestinal tract.
- BioWa, Inc. licensed POTELLIGENT®antibody technology to Genentech, Inc.
- Development of the process of L-tyrosine mass production by fermentation (a world first).
|
| 2005 |
- Completion of the transition to an operating holding company; pharmaceuticals and bio-chemicals are its main pillars.
- Spun off its food business, establishing Kyowa Hakko Food Specialties Co., Ltd.
- Establishment of renewed BioFrontier Laboratories by integrating former BioFrontier Laboratories with Tokyo Research Laboratories.
- Release of plant-based glucosamine produced by fermentation (a Japan first).
|
| 2004 |
- Kyowa Yuka Co., Ltd., inherited its chemicals operation and made a new start as Kyowa Hakko Chemical Co., Ltd.
- Establishment of Kyowa Hakko Pharmaceuticals (Suzhou) Co., Ltd in China, the company's first drug production base overseas.
- Development of a new method for industrially producing di-peptides, which consist of a pair of amino acids.
- Finding a substance related to “koku” (good body taste) of foods from mature cheese.
|
| 2003 |
- Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.
- Licensed independently-developed pill manufacturing technology (Exlub/Solblet) to Eurand.
- Release of Desmopressin Spray 10 Kyowa, a treatment for nocturnal enuresis.
- Release of the high sensitivity measuring reagent BNP for diagnosis of heart disease.
|
| 2002 |
- Transfer of alcoholic beverage business to Asahi Breweries Ltd.
|
| 2001 |
- Release of Allelock, an anti-allergic drug.
- Development of an innovative antibody technology (POTELLIGENT®) that greatly enhance antibody activity.
|
| 2000 |
- Development of the commercial production process of oligosaccharides by fermentation.
|
| 1999 |
- Development of the EXLUB external lubrication tableting system.
- Release of Navelbine, an anticancer drug.
- Determination of the whole genome sequence of Corynebacterium glutamicum.
- Release of Meditransnitro, a transdermal nitroglycerin product.
|
| 1998 |
- Initiation of the marketing of Navoban, an oral anti-emetic.
|
| 1997 |
- Release of Imagenil, a non-ionic X-ray contrast medium.
|
| 1994 |
- Release of Neu-up, a recombinant human G-CSF derivative as an anti-neutropenia.
- Release of Determiner HDL-C, a diagnostic reagent for HDL cholesterol.
- Release of low-temperature-resistant yeast for bread production (a world first).
|
| 1993 |
- Initiation of drug sales in the UK.
|
| 1992 |
- Establishment of Kyowa Pharmaceutical, Inc. in the USA.
|
| 1991 |
- Release of Depakene R, an anti-epileptic drug.
- Release of Activacin, a thrombolytic agent.
- Release of Coniel, a remedy for hypertension and agina pectoris.
|
| 1990 |
- Establishment of Medical Representative Offices in New York and Düsseldorf, as pharmaceuticals development base.
|
| 1989 |
- Release of Acenalin, a gastroprokinetic drug.
- Establishment of Kyowa Hakko (H.K.) Co., Ltd.
|
| 1988 |
- Establishment of Kato Memorial Bioscience Foundation.
|
| 1987 |
- Release of Celtect, an anti-allergic drug.
|
| 1985 |
- Release of Fortimicin, an aminoglycoside antibiotics.
|
| 1983 |
- Death of the company's founder Benzaburo Kato.
|
| 1982 |
- Release of Sagamicin, an aminoglycoside antibiotics.
- Release of Nauzelin, a gastrointestinal drug.
|
| 1981 |
- Establishment of the Bio Business Headquarters.
- Establishment of the Clinical Reagents Division as an independent company, Kyowa Medex Co., Ltd.
|
| 1978 |
- Release of Glumal, a drug for digestive ulcer.
- Release of Inovan, an agent to improve acute circulatory failure.
|
| 1977 |
- Received the Environment Agency Secretary's award for recycling of fermentation liquid waste and improvement of water quality.
|
| 1975 |
- Release of Depakene, an anti-epileptic drug.
- Release of Determiner TC·FC, a diagnostic reagent.
|
| 1973 |
- Establishment of Kyowa Hakko Europe GmbH.
|
| 1971 |
- Release of Leunase, an anticancer drug.
|
| 1969 |
- Establishment of Kyowa Hakko U.S.A., Inc.
- Establishment of Pharmaceutical Research Institute.
|
| 1967 |
- Establishment of the Chemical Business Headquarters.
- Release of 5-FU, an anticancer drug, and Acetylspiramycin, an antibiotic drug.
|
| 1966 |
- Establishment of the Food Business Headquarters.
- Split Daikyowa Sekiyu Kagaku Co., Ltd into two companies, establishing Kyowa Yuka Co., Ltd. as a separate company formed from the production division for ethylene-propylene-derived products.
- Received the Japan Academy Prize for research on amino acid production by fermentation as the first winner from a corporate entity.
|
| 1965 |
- Establishment of the Pharmaceutical Business Headquarters.
|
| 1964 |
- Release of Glumin, a remedy for peptic ulcers.
|
| 1963 |
- Initiation of full-scale involvement in the pharmaceutical business.
- Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.
|
| 1958 |
- Invention of the process of L-lysine production by fermentation.
- Release of a plant growth regulator, Gibberellin Kyowa. Contributed to the production of seedless grapes.
|
| 1956 |
- Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.
- Invention of the process of L-glutamic acid production by fermentation (a world first).
Pioneered the major business industry of amino-acid fermentation (beginning of involvement in biochemical / food-related business operations).
|
| 1951 |
- Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).
|
| 1949 |
- Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.
|
| 1948 |
- Initiation of Japan's first mass production of acetone butanol from syrup (beginning of involvement in chemical business operations).
|
| 1944 |
- Initiation of fermentative alcohol (absolute alcohol) manufacturing.
|
